Short-course neoadjuvant in situ vaccination for murine melanoma
暂无分享,去创建一个
Amy K. Erbe | S. Gillies | V. Subbotin | A. Rakhmilevich | P. Sondel | A. Erbe | Jen Birstler | D. Komjathy | Matthew Rodriguez | Arika S Feils | A. Stuckwisch | Taylor J Aiken | J. Birstler | A. Feils
[1] Amy K. Erbe,et al. In situ Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response , 2020, Frontiers in Immunology.
[2] J. Khan,et al. Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2 , 2020, Clinical Cancer Research.
[3] J. Taube,et al. Neoadjuvant checkpoint blockade for cancer immunotherapy , 2020, Science.
[4] P. Ascierto,et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. , 2019, European journal of cancer.
[5] J. Madore,et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome , 2019, Oncoimmunology.
[6] E. Ranheim,et al. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma , 2018, Cancer Immunology, Immunotherapy.
[7] P. Harari,et al. Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites , 2018, Cancer Immunology Research.
[8] D. Elder,et al. Association Between Patient Age and Lymph Node Positivity in Thin Melanoma , 2017, JAMA dermatology.
[9] A. Korman,et al. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model , 2017, The Journal of Immunology.
[10] M. Smyth,et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. , 2016, Cancer discovery.
[11] P. Harari,et al. In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. , 2016, Cancer research.
[12] E. Steyerberg,et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. , 2015, The Lancet. Oncology.
[13] J. Becker,et al. Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses , 2014, Cancer Immunology Research.
[14] S. Spiegel,et al. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. , 2013, Surgery.
[15] G. Botti,et al. Sentinel Node Biopsy in Thin and Thick Melanoma , 2013, Annals of Surgical Oncology.
[16] C. Garbe,et al. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up , 2011, Cancer Immunology, Immunotherapy.
[17] J. Bramson,et al. Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination. , 2009, Cancer research.
[18] S. Gillies,et al. Intratumoral immunocytokine treatment results in enhanced antitumor effects , 2008, Cancer Immunology, Immunotherapy.
[19] M. Sabel,et al. Neoadjuvant intratumoral cytokine‐loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti‐tumor immunity , 2006, Journal of surgical oncology.
[20] T. Warner,et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Rainer Fietkau,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.
[22] C. Garbe,et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases , 2003, British Journal of Cancer.
[23] M. Wiznerowicz,et al. Antitumor effects of the combination therapy with TNF-α gene–modified tumor cells and interleukin 12 in a melanoma model in mice , 2000, Cancer Gene Therapy.
[24] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Becker,et al. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[26] K. Takamiya,et al. Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[27] D. Pardoll,et al. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression , 1994, The Journal of experimental medicine.
[28] J. Mate,et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.
[29] S. Gillies,et al. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Silagi. CONTROL OF PIGMENT PRODUCTION IN MOUSE MELANOMA CELLS IN VITRO , 1969, The Journal of cell biology.
[31] M. Shinoda,et al. Title A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus ( JCOG 9907 ) , 2017 .
[32] E. Mittendorf. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden , 2014 .
[33] L. Tanoue,et al. The National Comprehensive Cancer Network , 1998, Cancer.
[34] M. Shinoda,et al. A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) , 2011, Annals of Surgical Oncology.